+ T cell exhaustion impedes control of chronic viral infection; yet how new T cell responses are mounted during chronic infection is unclear. Unlike T cells primed at the onset of infection that rapidly differentiate into effectors and exhaust, we demonstrate that virus-specific CD8 + T cells primed after establishment of chronic LCMV infection preferentially generate memory-like transcription factor TCF1 + cells that were transcriptionally and proteomically distinct, less exhausted, and more responsive to immunotherapy. Mechanistically, adaptations of antigen-presenting cells and diminished T cell signaling intensity promoted differentiation of the memorylike subset at the expense of rapid effector cell differentiation, which was now highly dependent on IL-21-mediated CD4 + T cell help for its functional generation. Chronic viral infection similarly redirected de novo differentiation of tumor-specific CD8 + T cells, ultimately preventing cancer control. Thus, targeting these T cell stimulatory pathways could enable strategies to control chronic infection, tumors, and enhance immunotherapeutic efficacy.
SUMMARY

CD8
+ T cell exhaustion impedes control of chronic viral infection; yet how new T cell responses are mounted during chronic infection is unclear. Unlike T cells primed at the onset of infection that rapidly differentiate into effectors and exhaust, we demonstrate that virus-specific CD8 + T cells primed after establishment of chronic LCMV infection preferentially generate memory-like transcription factor TCF1 + cells that were transcriptionally and proteomically distinct, less exhausted, and more responsive to immunotherapy. Mechanistically, adaptations of antigen-presenting cells and diminished T cell signaling intensity promoted differentiation of the memorylike subset at the expense of rapid effector cell differentiation, which was now highly dependent on IL-21-mediated CD4 + T cell help for its functional generation. Chronic viral infection similarly redirected de novo differentiation of tumor-specific CD8 + T cells, ultimately preventing cancer control. Thus, targeting these T cell stimulatory pathways could enable strategies to control chronic infection, tumors, and enhance immunotherapeutic efficacy.
INTRODUCTION
CD8
+ cytotoxic T lymphocytes (CTL) control viral infections by directly killing infected cells, secreting proinflammatory cytokines, and forming memory that protects against re-exposure.
Although most viral infections trigger a potent CTL response that resolves infection, certain viruses are capable of outpacing the immune response and establishing a chronic infection. In response to prolonged viral replication and antigen stimulation the host initiates an immunosuppressive program that actively suppresses antiviral T cell function leading to CTL exhaustion and preventing subsequent control of infection (Wherry and Kurachi, 2015) . Our understanding of T cell activation and exhaustion in chronic infection comes largely from studies characterizing T cells primed at the onset of infection, yet this represents only a fraction of the antiviral T cell response generated during chronic infection (Allen et al., 2005; Henn et al., 2012; Le et al., 2017; McGranahan et al., 2016; Vezys et al., 2006) . On the other hand, little is known about how new T cell responses are mounted throughout chronic infection, despite their importance to balance attrition of exhausted cells, to target virus-escape mutants and neo-antigens, to control secondary infections and tumors that arise in the chronic infection, and for immunotherapy to rebuild the antiviral response. At the onset of chronic infection, CD8 + T cells are activated in a setting of increasing virus titers and shifting from a proinflammatory to immunosuppressive environment that progressively leads to exhaustion (Angelosanto et al., 2012; Brooks et al., 2006; Wherry et al., 2003a) . However, in an established chronic viral infection, this immunosuppressive environment is already entrenched and naive T cells being primed would immediately encounter established chronic virus and inflammation, altered antigen-presenting cell (APC) populations (and functions), and a long-since established suppressive environment (Cunningham et al., 2016; Snell et al., 2017) . These environmental differences between the onset and the established chronic infection could all potentially affect CD8 + T cell activation, function and differentiation; having consequences toward long-term viral control and for immune restorative therapies, including hematopoietic stem cell engineering approaches that are inherently dependent on the activation of de novo T cell responses within established chronic viral infection (Kitchen et al., 2012) . Activated CD8 + T cells in chronic viral infection differentiate into two subsets: TCF1 + (T cell factor1) and TCF1 À CD8 + T cells (He et al., 2016; Im et al., 2016; Leong et al., 2016; Utzschneider et al., 2016; Wu et al., 2016) . The vast majority of antiviral CD8 + T cells are composed of granzyme and perforin expressing terminally differentiated TCF1 À effector cells. TCF1 + cells possess decreased effector function but maintain proliferative capacity and an ability to reseed the TCF1 À cells throughout chronic infection. Consequently, the TCF1 + subset is essential for long-term virus control. Yet, the molecular and cellular mechanisms that drive the fate choices of these CD8 + T cell subsets, how they are modulated through the course of chronic infection, or how to therapeutically induce these subsets are not understood.
Herein, we demonstrate that unlike CD8 + T cells primed at the onset of chronic LCMV infection that rapidly differentiated into effectors and exhausted, CD8 + T cells primed after chronic infection was established preferentially generated TCF1 + memory-like T cells that resisted contraction, were less exhausted, had increased functionality, and responded better to anti-PDL1 immunotherapy. Changes to the priming APC diminished the strength of activating TCR and costimulatory signals inducing TCF1 + memory-like CD8 T cell programming. Thus, by modulating APC and T cell signal strength, CD8 + T cells primed in the established infection are skewed away from rapid effector differentiation and exhaustion and are enabled for the sustained battle against a long-term chronic infection.
RESULTS
Virus-Specific CD8 + T Cells Primed in an Established Persistent Infection Undergo an Alternative Pathway of Transcriptional and Effector Differentiation
To investigate how naive CD8 + T cells (Tn) differentiate in the environment of an established persistent infection compared to at the onset of infection, we adoptively transferred LCMVGlycoprotein (GP) 33-41 specific CD8 + TCR transgenic (P14)
T cells into mice that had been chronically-infected 21 days earlier with LCMV-Clone 13 (Cl13), or into naive mice that were then immediately infected with Cl13, enabling comparison of the same cells primed at different times of infection. Importantly, transgenic P14 CD8 + T cells recapitulate the host-derived GP 33-41 tetramer response to Cl13 (Brooks et al., 2006) . In the LCMV system, chronic virus replication peaks at $8 days after infection and then decreases to set-point and is maintained systemically for 60-80 days ( Figure S1A ). By 21 days, the viral titers were $2 logs lower than at their peak from the onset of infection and remained similar at continual levels in the spleen throughout the established chronic infection ( Figure S1A ), consistent with the physiologic evolution of chronic viral infections. The rapid virus expansion was also observed following acute LCMV-Armstrong infection, despite the containment of the acute infection at 8 days ( Figure S1A ), indicating that it is not the initial high spike of virus itself, but rather many factors that cause T cell exhaustion and viral persistence. Figure 1D and 1F, S1D), which drive CD8 + T cell effector function and terminal differentiation (Joshi et al., 2007; Xin et al., 2016) . Conversely, Tlp cells exhibited few characteristics of CTL effector differentiation, having low expression of Tbet and Blimp1 and failing to produce GzmB (Figures 1D -1G, S1D). Instead, Tlp cells had higher expression of the transcriptional regulator Eomesodermin (Eomes) and sustained high TCF1 expression ( Figures 1D-1G and S1D), transcription factors that endow self-renewal capacity and are associated with long-term memory T cell survival. Thus, Tep cells exhibited a CTL effector signature characterized by heightened expression of multiple activation and inhibitory molecules, while Tlp cells exhibited a signature associated with memory and longevity. By 8 days after priming, CD8 + Tep cell numbers were increased by 20-to 100-fold in multiple tissues (Figure 2A ). CyTOF analyses demonstrated Tep and Tlp were largely exclusive in high dimensional space, indicating a continued divergence between their differentiation states ( Figures 2B and 2C) . By day 8, CD62L, CD25, and CD127 were downregulated on both Tep and Tlp cells ( Figure S2A ), whereas Tep cells exhibited higher expression of the activation and/or inhibitory proteins CD122, CD11c, PD1, PDL1, Tim3, and Lag3, as well as increased expression of Tbet, Blimp1, and GzmB ( Figures  2C-2F Figure S2E for backgating) demonstrated that the Tlp effectors that were present expressed a less activated and exhausted signature, characterized by decreased expression of many inhibitory and/or terminal differentiation proteins ( Figure 2G ). This pattern was similar when we examined GzmB À TCF1 + subsets as well ( Figure 2G ), suggesting that regardless of effector cell or memory-like cell differentiation, Tlp cells were less activated and exhausted overall. In line with this, the The programming of Tlp cells suggested that this population might possess long-term survival potential (He et al., 2016; Im et al., 2016; Leong et al., 2016; Utzschneider et al., 2016; Wu et al., 2016) . While both TCF1 + and GzmB + Tep cells contracted from their peak numbers after day 8 post-priming, these populations were sustained or increased in CD8 + Tlp cells between day 8
and 21 after priming ( Figure 3A ). GzmB expression by Tlp cells was also higher 3 weeks after priming compared to Tep cells on a per cell basis ( Figure 3A) , and a higher proportion of Tlp cells maintained cytolytic activity ( Figure 3B Figure S3A ). Further, like the splenic Tlp cells, the single cell expression levels of GzmB were increased and PD1 decreased in liver Tlp cells ( Figure S3A ), indicating that the altered differentiation and decreased expression of inhibitory receptors occurred in both lymphoid and non-lymphoid tissues. (He et al., 2016; Im et al., 2016; Utzschneider et al., 2016) . To test this, Tep and Tlp cells were primed for 21 days and then mice were treated with anti-PDL1 blocking antibody. For this experiment, the mice were CD4 + depleted prior to infection to determine intrinsically how the Tep and Tlp cells responded to anti-PDL1 without the secondary effects of decreasing virus loads. Following anti-PDL1 blockade, an average 19-fold expansion of Tlp cells in the blood was observed with robust responses in all treated mice, whereas Tep cells expanded with only an average 8-fold increase in anti-PDL1 treated mice ( Figure 3F) . A similar enhanced responsiveness was observed in the spleen, with Tlp cells responding to anti-PDL1 therapy in $91% of mice, whereas Tep responsiveness was only observed in 50% of treated mice ( Figure 3F ). When the fold expansion was quantified using the TCF1 + cells from isotype treated mice as baseline (the cells that give rise to the anti-PDL1 induced CD8 + T cells), the fold change in Tlp TCF1 + and GzmB + cells was substantially higher than observed for Tep cells ( Figure 3F ). The enhanced expansion of Tlp cells was independent of changes in viral titers, because the therapy purposefully did not lower viral titers in the late prime condition and only minimally in the early prime condition ( Figure S3B ). Tlp and Tep cell differentiation pathways diverged early following priming (Figure 1 ), suggesting that APCs may alter the induction of these subsets. Although there were fewer dendritic cells (DCs) in the midst of infection compared with 1 day after infection, the proportions of CD8a + and CD11b + DC subsets were similar ( Figure S4A ), indicating that a DC subset skewing was likely not driving differential priming. CD8a + DCs and macrophages Table S1 ). Data represent 3 or more independent experiments with 3-5 mice per group. Error bars indicate SD. Significance was determined by one-way ANOVA unless otherwise indicated. *p < 0.05. See also Figure S1 and Table S1 . in the established infection expressed less MHC I than those 1 day after infection; and CD80 and CD86 expression was also dramatically reduced on DCs and macrophages during infection, similar to levels seen in naive mice ( Figures 4A and S4B ). The diminished APC activation state during infection corresponded with reduced Nur77 expression (a surrogate marker for TCR signaling) on Tlp compared to Tep cells at priming ( Figure 4B ). Together, this suggested that the distinct differentiation of Tlp cells may result from decreased TCR and/or costimulatory signals from priming APCs. To test the need for strong stimulation to generate rapid effector cells, we supplemented TCR and costimulatory signals to Tlp cells in vivo using agonistic anti-CD3 and/or anti-CD28 antibodies. While anti-CD3 or anti-CD28 alone failed to robustly generate GzmB + effector cell differentiation, simultaneous enhancement of TCR and costimulatory signaling at the time of Tlp priming induced the majority of TCF1 + cells to become GzmB + CD25 + cells ( Figure 4C ). Increasing the amount of TCR and costimulation also drove Tlp GzmB + effector cell differentiation in CD4 À/À mice ( Figure S4C ), indicating that the decreased TCR and costimulatory signal strength intrinsically inhibited CD8 + T cell effector differentiation in the established chronic infection. The antibody treatments did not significantly alter the number of virus-specific CD8 + Tlp cells at this time point ( Figure S4D ), demonstrating that changes in the proportions of Tlp subsets reflected conversion between TCF1 + and GzmB lineages. Thus, decreases in signaling strength maintained memory-like TCF1 + differentiation and limited rapid effector cell differentiation in the established chronic infection.
As DCs are fundamental for the priming of CD8 + T cells at the onset of LCMV infection (Probst and van den Broek, 2005) , we used CD11c-DTR mice to test their role in priming of Tlp cells. DT treatment just prior to late priming resulted in $90-95 percent depletion of DCs, and diminished the proliferation and number of Tlp cells ( Figure S4E ). The residual priming of Tlp cells likely resulted from incomplete DC depletion or the ability of other APC populations, such as macrophages to prime CD8 + T cells in the absence of DCs. As DCs do significantly contribute to Tlp cell priming, we chose this cell type to test whether effector Tlp cell differentiation could be restored in the established infection if the quality of APC were enhanced. We transferred GP 33-41 peptide-pulsed bone marrow derived DCs (bmDC) into Cl13 infected beta 2-microglobulin (B2m) À/À mice that lack the ability to endogenously present antigen to CD8 + T cells, thus restricting priming to the transferred DC while still maintaining the early and late priming environments and viral titers. Transfer of bmDC effectively induced high level Tlp GzmB + effector cell differentiation to the same level as Tep cells ( Figure 4D ). The role of priming DC was further corroborated using infection of mice with a variant of Cl13 that lacks the GP 33-41 epitope recognized by P14 T cells (Cl13V35A), but contains all other LCMV-derived CD8 + T cell epitopes and has analogous replication kinetics to wild-type Cl13 (Puglielli et al., 2001) . DC transfer in this system also generated Tlp GzmB + effector differentiation ( Figure S4F ), demonstrating that rapid de novo effector T cell differentiation is possible in the chronic infection when strong T cell stimulation is provided. Thus, the decreased T cell stimulatory capacity during the established chronic infection preferentially sustained TCF1 + memory-like cells and limited effector differentiation. Figure 5A ). Gene Set Enrichment Analysis (GSEA) identified upregulation of gene signatures of DNA replication, translation, ribosome biogenesis, and glycolysis in Tep cells (Figure 5B and Table S2 ), in line with enhanced Tep cell activation and blasting (Figure 1, S1 ). The myc pathway (which promotes glycolysis) (Verbist et al., 2016) and the mTORC1 signaling pathway were also enriched in Tep cells ( Figure 5B ), consistent with the need for glycolytic metabolism to provide the energetic needs for CD8 + effector T cell differentiation, and mTORC1's role in driving terminal differentiated effector-like T cells (Buck et al., 2017; Pollizzi et al., 2015) . Tlp cells on the other hand, showed enrichment in pathways involved in cell adhesion, integrin interactions, cell motility, and the Focal Adhesion Kinase (FAK) pathway ( Figure 5B and Table S2 ). A role of the FAK pathway is to modulate the T cell:APC interaction, and the increase in this pathway, which promotes movement from interaction, suggests that the decreased TCR and costimulatory signals in Tlp Figure S2 . Figure 5C and Table S3 ). While Tep cells had increased expression of genes associated with T cells in chronic LCMV, Tlp cells showed upregulation of genes associated with CD8 + T cells in acute LCMV (Figure 5C  and Table S3 ), indicating the early divergence in exhaustion programming. Tep cells expressed high levels of multiple genes associated with enhanced effector activation and/or exhaustion including the costimulatory receptors and ligands Tnfrsf8 (CD30), Tnfrsf4 (OX40), Tnfrsf9, Tnfsf9 (4-1BBL and 4-1BB, respectively), cytokines IFNg, IL21, and IL10, exhaustion factors Tigit, Entpd1 (CD39), Pdcd1 (PD1), CD276 (B7-H3), Pdcdlg2 (PDL2), Havcr2 (Tim3), and the Metallothioneins Mt1, Mt2, and Mt3 ( Figure 5D ) that have been identified to promote CD8 + T cell dysfunction (Singer et al., 2016) . Further, multiple cytolytic factors: Prf1, Gzmb, Gzma, Fasl, and Gzmc, were increased in Tep cells, whereas Tlp cells instead had decreased expression of inhibitory factors (except Lag3) ( Figure 5D ). Tlp cells were enriched in a variety of genes involved in programming long-lived immunity and T cell memory, including IL21R (Allard et al., 2007) , Tnfsf8 (CD30L) (Nishimura et al., 2005) and CD27 (Wherry et al., 2003b ) and increased expression of many transcription factors present in CD8 + memory T cells and selfrenewal, including Pou6f1, Bach2, Eomes, Id3, Tcf7 (TCF1), Bcl6, Foxo1, and Lef1 ( Figure 5D ). Metabolically, sterol and fatty acid metabolism pathways were increased in Tlp cells, including increased SREBF1 and 2 (SREBP1 and 2), as well as increased expression of Rictor, which is involved in the mTORC2 pathway that guides CD8 + T cell memory differentiation (Figure 5D ) (Buck et al., 2017; Pollizzi et al., 2015) . In contrast, Tep cells exhibit a terminally differentiated transcriptome, including increased expression of Prdm1 (Blimp1), Batf, Maf1, Zbtb32, tbx21 (Tbet), and Myc ( Figure 5D ), which drive CTL effector differentiation and function (Giordano et al., 2015; Kuroda et al., 2011; Shin et al., 2017; Xin et al., 2016) . Thus, Tep cells very rapidly exhibited a transcriptional profile of robust activation, effector differentiation, and dysfunction, whereas Tlp cells had increased expression of genes involved in memory differentiation and maintenance. Consistent with the expression of CD25 ( Figures 1C and 1D ) and increased expression of STAT5a RNA ( Figure 5D ), an IL-2 signaling gene signature was elevated in Tep cells ( Figure 5E ). IL-2 is a strong inducer of STAT5a phosphorylation and basal pSTAT5a levels were $10-fold higher in Tep cells ( Figure 6A ). Upon stimulation with IL-2, Tep cells robustly phosphorylated STAT5a, while Tlp cells phosphorylated STAT5a to a much lesser extent that was similar to basal IL-2 responsiveness in Tn cells ( Figure 6A ). In vivo antibody blockade of IL-2 at the onset of infection significantly reduced GzmB producing Tep cells both in proportion and number, whereas it had a minimal effect on Tlp differentiation ( Figure 6B ), indicating that IL-2 promoted effector CD8 + T cell differentiation at the onset of chronic infection, but that as infection progresses, other factors must take over this role.
Instead of IL-2, Tlp cells had enrichment of an IL-21 signaling gene signature and Tlp cells expressed significantly higher levels of IL-21R compared to Tep cells ( Figures 5D and 5E ). This was unexpected since the only previously identified role of IL-21 in chronic infection was to sustain long-since generated CD8 Figure S5A ). Inhibition of IL-21R signaling in vivo with an anti-IL21R blocking antibody (Zhang et al., 2015) did not affect Tep cell differentiation, whereas IL-21R blockade in the midst of infection reduced the proportion of effector GzmB producing Tlp cells by over 50% and almost doubled the frequency of TCF1 + Tlp cells (Figure 6C) . The blockade of IL-21R signaling in the established chronic infection led to a decline in the overall number of Tlp cells, largely due to the decrease in GzmB + effector Tlp cells ( Figure 6C ). Thus, IL-21 signaling is critical for CD8 + effector Figure 6D ). However, in the absence of virus-specific CD4 + T cell help, CD8 + Tlp cells were decreased $5-to 10-fold numerically, had even further decreased GzmB + effector differentiation, and had dramatically reduced cytokine producing capacity (Figures 6D and S5B) . The decreased number of total Tlp cells in the absence of CD4 + help was largely due to the decreased ability to generate GzmB + effector cells, while the number of TCF1 + Tlp cells was either not or only minimally decreased by lack of CD4 + help ( Figure 6D ). The diminished Tlp effector generation over the 8 day priming and expansion period in the absence of CD4 + help was not due to changes in virus levels since no significant difference in viral titers was observed between undepleted or CD4 + depleted mice in this time (day 8 or day 29 after infection for Tep and Tlp cell priming, respectively; Figure S5C ). Chronic viral infections are associated with enhanced tumor formation, yet the underlying mechanisms for why this occurs are unclear. We hypothesized that like the virus-specific Tlp cells, the changes in the APC would similarly alter de novo priming of CD8 + T cells encountering a tumor in the presence of the chronic viral infection. To determine whether the altered effector differentiation observed by virus-specific Tlp cells spreads to secondary responses, we administered ovalbumin (OVA) expressing EG7 tumors to naive or chronically infected mice. Twelve days after tumor injection there were decreased tumorspecific OT1 tumor infiltrating lymphocytes (TILs) in chronically-infected mice compared with mice that received tumor alone ( Figure 7A ). Like virus-specific CD8 + Tlp cells, tumorspecific CD8 + TILs in chronically-infected mice were all activated (based on proliferation dye dilution), but expressed less Tbet, increased Eomes and had a differentiation pattern skewed toward TCF1 + cells and decreased GzmB + effector cells ( Figures  7B and 7C) . The tumor-specific CD8 + TILs in the chronicallyinfected mice also expressed less GzmB on a per cell basis, analogous to virus-specific Tlp cells ( Figure 7C ). Although the goal of the experiment was to determine whether CD8 + T cell differentiation was similarly altered against a secondary (nonrelated) challenge in the chronic infection, it was interesting to observe that wherein the naive mice were able to ultimately control the tumor at later time points at the dose given, the chronically infected mice were not ( Figure S6A ). When naive OT1 cells were transferred prior to tumor, the naive mice more rapidly controlled the tumor compared to no OT1 transfer controls ( Figures 7D and S6A ). On the other hand, OT1 transfer prior to tumor administration in the chronic infection did not control the tumor, although it did significantly enhance tumor control at later time points (albeit with a slower kinetic and to a lesser extent then in naive mice; Figures S6A ). These kinetics indicated that the tumor-specific OT1 cells were functioning in the naive and chronically infected conditions, and that the addition of OT1 re-enforced the observed tumor kinetic in the given condition (likely due to their increased precursor frequency), but did not change the ultimate outcome otherwise observed when no cells were transferred. The decreased tumor-specific effector cell priming and the inability to control tumor growth in the chronic infection was overcome by providing OVA-peptide labeled bmDC that strongly activated the tumor-specific CD8 + T cells ( Figures 7E and S6B) , indicating that the changes in the APC spread to alter differentiation of T cells targeting tumors that arise in chronic infection, but that with the proper priming APC and CD8 + T cell activation, the tumor can be rapidly controlled during the chronic infection despite the pervasive immunosuppressive environment.
DISCUSSION
Although previous work has extensively characterized the differentiation and exhaustion of antiviral CD8 + T cells primed at the onset of chronic viral infection, little is known about how virusspecific or secondary antigen-specific de novo CD8 + T cell responses are mounted once chronic infection is established. We demonstrate that whereas CD8 + T cells primed at the onset of chronic infection almost entirely became short-term effectors and rapidly exhausted, CD8 + T cells primed after the infection is established acquired a distinct transcriptional profile that allowed them to resist exhaustion and to retain long-term killing in the face of ongoing viral replication. Tep cells received increased TCR and costimulatory signaling, blasted more, and rapidly differentiated within the first 60 hr post-priming into effector cells with high expression of multiple activation and inhibitory markers. In contrast, Tlp cells received decreased TCR and costimulatory signals and although were equally proliferative, remained in a less differentiated state after priming, failing to produce GzmB, retaining TCF1 and expressing Eomes and multiple other transcription factors and surface proteins associated with CD8 + memory. By day 8, Tlp cells did generate a proportion of GzmB + effector cells (albeit to a much lesser extent and expressing less GzmB at the single cell level then Tep cells), while preserving a high proportion of the memorylike subset. Both at the population level, and in particular in the GzmB + effector subset, Tlp cells expressed a broad signature of decreased exhaustion and long-term survival potential. As chronic infection progressed Tlp cells minimally contracted, had elevated GzmB expression and killing ability, and continued to express decreased levels of inhibitory and activation receptors. The definition of T cell exhaustion is evolving from solely a description of cytokine levels to the integration of multiple criteria including functional parameters (e.g., cytokines, granzymes), distinct transcriptional and metabolic profiles, the combinatorial and quantitative expression of inhibitory receptors, and the ability to respond to immunotherapy (Bengsch et al., 2018) , By all these criteria, the Tlp cells are less exhausted than their Tep cell counterparts. Due to the low numbers of Tlp cells generated, we were unable to perform transfer experiments to identify the ability of these cells to control infection compared to Tep cells. However, based on the ability of the TCF1 + population to seed the GzmB effector pool over time (He et al., 2016; Im et al., 2016; Leong et al., 2016; Utzschneider et al., 2016; Wu et al., 2016) and Tlp cells lower level of inhibitory receptors, the Tlp cells could likely lead to enhanced long-term control of chronic viruses. Overall, the change in stimulation, differentiation, and function of Tlp cells may be an adaptation of the immune system to the ''realization'' that it is no longer engaged in a short battle, but rather fighting a protracted war and needs to promote responses that are better suited for this environment. Although many changes in the immune environment can suppress T cell responses in chronic infection, the decreased Tlp effector cell priming was initiated by intrinsic changes in the APC that led to decreased T cell stimulation. While dynamic modulation of APC subsets and function has been previously reported in Cl13 (Cunningham et al., 2016; Sevilla et al., 2004) , its impact on CD8 + T cell priming, differentiation and function in vivo has not been determined. We now demonstrate that this decreased T cell stimulation specifically drove memorylike TCF1 + differentiation at the expense of rapid effector differentiation. The DC transfer experiments and the in vivo anti-CD3 and anti-CD28 treatments demonstrated that rapid Tlp cell effector differentiation is possible in the environment of the established chronic infection. Neither anti-CD3 nor anti-CD28 alone could drive effector differentiation, thus, it is not just that one strong stimulus can overcome these signaling defects but that enhancement of both TCR and CD28 signaling is needed to drive effector differentiation from the TCF1 + populations in the chronic infection. Further, in the presence of strong T cell activation signals, the need of Tlp for CD4 + T cell help was overcome, analogous to Tep priming at the onset of infection. Thus, with strongly stimulatory APCs, effector cells can be induced in the established chronic infection, whereas lower stimulation maintains TCF1 differentiation and guides the observed differentiation program. It should be noted that we are not suggesting that the immune environment itself does not also modulate Tlp cell responses. In addition to alterations in APC, the environment and the reduction in virus titers in established chronic infection likely also contribute to modulate Tlp cells, potentially augmenting the differentiation into TCF1 + cells, and likely further enabling the decreased levels of exhaustion. Strong antigenic signaling at the onset of chronic infection increased CD25 expression that allowed IL-2 signaling to help differentiate TCF1 + CD8 + T cells into GzmB producing effectors, with minimal involvement from IL-21 signaling. In the midst of infection low antigenic signaling failed to induce CD25 expression, and coupled with the progressive switch from IL-2 to IL-21 production with viral persistence (Elsaesser et al., 2009) , eventually programmed a fraction of the TCF1 + cells to differentiate into less exhausted effector cells, while still maintaining the memory-like reservoir. This requirement for IL-21 signaling at the time of priming is distinct from previous observations in which IL-21 had no notable effect on the priming or differentiation of virus-specific CD8 + Tep cells at the onset of infection (Elsaesser et al., 2009; Frö hlich et al., 2009; Yi et al., 2009 ), but functioned exclusively to sustain the previously activated cells at later time points in chronic infection. Consistent with the strong requirement for IL-21 signaling, CD4 + T cell help was critical to promote the eventual Tlp effector cell differentiation and function in the late priming condition where APC activation is diminished, whereas CD4 + T cell help was dispensable for Tep cell priming. These data suggest that in situations wherein CD4 + T cell help is progressively limiting such as with HIV infection, diminished CD8 + T cell responses may be further compounded by lack of de novo effector cell priming to sustain the ongoing response, control virus escape mutants, or to fight opportunistic cancers that arise. Thus it is interesting to speculate that the progressive switch from IL-2 toward IL-21 producing CD4 + T cells evolved not only to sustain the CD8 + T cells generated at the onset of infection, but also to promote effector cell + memory-like cell generation and decreased levels of inhibitory receptors (Blackburn et al., 2009; He et al., 2016; Im et al., 2016; Leong et al., 2016; Utzschneider et al., 2016; Wu et al., 2016) , suggesting that even among the total TCF1 + pool, distinct TCF1 + populations could be preferentially enhanced by anti-PDL1 immunotherapy. Interestingly, recent data has shown that tumors with mismatch repair defects that generate increased amounts of neo-antigens have enhanced responsiveness to checkpoint blockade (Le et al., 2017; Nebot-Bral et al., 2017) . Why these cells are specifically sensitive to checkpoint blockade is unclear, but it is interesting to speculate that the priming of de novo CD8 + T cell responses in the established tumor environment similarly skews CD8 + T cell fate commitment to generate cells that are better able to respond to checkpoint blockade. Thus, CD8 + T cells primed at different times in the chronic infection may disproportionately contribute to the immunotherapeutic response, with important ramifications for virus control and the design of vaccines and immunotherapies aimed at de novo inducing distinct antiviral CD8 T cell subsets. Many chronic viral infections are associated with increased incidence and poorer outcome to cancers. Although the mechanisms driving these relationships are likely many, mounting an initial CD8 + T cell response not well suited for immediate effector activity could allow tumors to develop that would otherwise be controlled by effector anti-tumor CD8 + T cells. Indeed, the environment in chronic infection similarly decreased rapid tumorspecific CD8 + T cell effector differentiation and in line with this, the tumor-specific CD8 + T cells primed in the chronic infection had diminished capacity to control tumor growth. Thus, while beneficial to sustain long-term immunity, this Tlp adaptation may in some instances come at a cost when immediate strong effector responses are desired to control pathogen or tumor. Transfer of tumor-peptide labeled DC at the time of tumor cell priming in chronically infected mice efficiently induced rapid and robust effector cell generation and efficient control of tumor growth, indicating that rapid effector cell differentiation against tumors and effective tumor control is possible in the environment of the chronic viral infection if strongly stimulatory APCs are present. Ultimately, targeting APC and these T cell fate determining pathways could lead to new therapies that actively control CD8 + T cell subsets and guide subsequent effector or memory responses to better control infection, tumors, and enhance responses to immunotherapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
(early priming) or (2) into mice that had been infected 21-25 days earlier with Cl13 (late priming). For experiments in which the mice were sacrificed at 60 hours after transfer, 250,000 P14 cells were transferred to enable detection at this early time-point.
DC adoptive transfer
Bone marrow-derived dendritic cells (BMDCs) were generated as previously described (Roney, 2013) . Briefly bone marrow cells from C57BL/6 mice were cultured in 20 ng/mL GM-CSF (BioLegend) with media changes at day 3, 6 and 8. 20 ng/mL IL-4 (BioLegend) was added to the culture at day 6 and day 8. Loosely adherent cells were harvested on day 10 and cultured with 100 ng/mL LPS (SigmaAldrich) for 20 hours. Cells were then pulsed with 1 mg/ml of LCMV-GP 33-41 (for P14 T cells) or OVA 257-264 (SIINFEKL; for OT-I T cells) peptide for 2 hours. Two million peptide pulsed BMDCs were injected per mouse.
EG7 tumor model 1x10 6 OT-I cells were injected into either naive or mice that had been persistently infected 21 days prior. One day later, 1x10 6 EG7 tumor cells (generously provided by Dr. Robert Prins, University of California, Los Angeles) were injected subcutaneously into both groups of mice. In certain experiments OVA 257-264 peptide-pulsed DCs were also injected on the same day as the tumor. Mice were sacrificed 12 days post-tumor injection. Tumors were digested using the Gentlemax tumor dissociation kit (Miltenyi). Tumor and single cell suspensions were acquired and analyzed by flow cytometry. (Table S1 ) and Fc block (CD16/32; in house) for 30 min at 4 C. Cells were fixed, permeablized and stained with metal tagged intracellular antibodies (Table S1 ) using the eBioscience Foxp3 / Transcription Factor Staining Buffer Set according to manufacturer's instructions. All antibody concentrations were used at saturating concentrations previously determined by titration. Cells were then incubated overnight in PBS (Multicell) containing 0.3% (ws/v) saponin, 1.6% (v/v) paraformaldehyde (diluted from 16%; Polysciences Inc) and 50 nM Iridium (Fluidigm). Cells were analyzed on a Helios or CyTOF-2 mass cytometer (Fluidigm). EQ Four Element Calibration Beads (Fluidigm) were used to normalize signal intensity over time and data analysis was performed. P14 T cells were gated on (DNA/Iridium + , single event length, cisplatin -, B220 lo NK1.1 lo , TCRb + , CD8a + Thy1.1 + ). t-SNE analyses were performed on the P14 cells (perplexity = 30, theta = 0.5, iterations = 1000, equal sampling).
Flow cytometry and intracellular cytokine stimulation
Single cell suspensions were prepared from organs and were stained ex vivo using antibodies to CD8 (53-6.7), Thy1.1 (H1S51), CD62L (MEL-14), CD25 (PC61), CD127 (A7R34), CD122 (TM-b1), 4-1BB (1AH2), CD27 (LG.3A10), PD1 (29F.1A12), Tim3 (215008), Lag3 (C9B7W), MHC I (AF6-88.5), CD80 (16-10A1), CD86 (GL-1), CD11c (3.9), CD11b (M1/70). All were from Biolegend with the exception of Thy1.1 (eBiosciences), 4-1BB (BD Biosciences), and Tim3 (R&D Systems). Staining for Tbet (4B10), Blimp1 (5E7), Granzyme B (GB11), (Biolegend), TCF1 (S33-966), (BD Biosciences), EOMES (Dan11mag), and Nur77 (12.14) (eBiosciences) was performed as directed using the Foxp3 / Transcription Factor Staining kit (eBiosciences). Samples were run on a FACS Verse (BD Biosciences) and data analyzed using Flow Jo software (Treestar).
For cytokine quantification, splenocytes were restimulated for 5 hours at 37 C with 2 mg/ml of MHC class I-restricted LCMV peptide GP [33] [34] [35] [36] [37] [38] [39] [40] in the presence of 50 U/ml recombinant murine IL-2 and 1 mg/ml brefeldin A (Sigma). Following the 5 hours in vitro restimulation, cells were stained with a fixable viability stain, zombie aqua (Biolegend), extracellularly stained as above with CD8, Thy1.1, and fixed, permeabilized (Biolegend cytokine staining kit) and stained with IFNg (XMG1.2), TNFa (MP6-XT22) and IL-2 (JES6-5H4) (Biolegend).
For phospho STAT3 and STAT5 staining, splenocytes were stimulated with 10 5 Units of IL-2 (Thermoscientific) or 200 ng/mL of IL-21 (R&D Systems) for 15 minutes at 37 C. Cells were then fixed immediately with 1% paraformaldehyde, then permeabilized with ice-cold 100% MeOH and stained with CD8 (53-6.7), Thy1.1 (H1S51) (Biolegend), pSTAT3 (pY705, clone 4/P-STAT3) and pSTAT5 (pY694, clone 47/Stat5) (BD Biosciences).
CTL Trogocytosis Assay
We used the trogocytosis assay to specifically measure the small population of transferred cells among the larger mixed group of endogenous virus-specific cells that would also lyse in a standard CTL assay. The trogocytosis assay was performed as described in (Daubeuf et al., 2006) . EG7 target cells were labeled with biotin at 1 mg/mL and then peptide labeled for 1 hour with 1 mM LCMVspecific GP 33-41 or ovalbumin-specific OVA 257-264 as a non-specific control at 37 C. Target cells were mixed with effector splenoctyes from Cl13 infected mice at a 1:1 ratio and incubated for 4 hours at 37 C. Following the incubation cells were spun down, supernatants removed and resuspended in cold PBS + 2 mM EDTA to dissociate cell conjugates. Cells were stained for CD8, Thy1.1, streptavidin-APC and subsequently analyzed by flow cytometry to quantify the level of trogocytosis by P14 cells from GP33 pulsed or OVA-pulsed EG7 cells.
RNA-seq P14 T cells were transferred into mice that had been infected 21 days earlier with Cl13 or into naive mice immediately infected with Cl13. Sixty hours post-infection mice were sacrificed and splenocytes from 4-5 mice were pooled and B cell depleted with anti-CD19 beads (Miltenyi). Single cell suspensions were then stained for virus-specific P14 cells using CD8 and Thy1.1 and FACSorted on a Moflo Astrios (Beckman Coulter) directly into RLT buffer (QIAGEN). RNA was isolated using a single cell RNA purification kit (Norgen Biotech Corp.) according to manufacturer's instructions. SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Clontech) was used per manufacturer's instructions for amplification of RNA and subsequent cDNA synthesis. All samples proceeded through NexteraXT DNA Library Preparation (Illumina) using NexteraXT Index Kit V1 or V2 Set A (Illumina) following manufacturer's instructions. A portion of this library pool was sent for sequencing on an Illumina NextSeq HighOutput, single read at the Princess Margaret Genomics Core Facility. An average of 400M reads were obtained per pool, with an average of 40M reads/sample across the entire dataset.
In vivo antibody treatments, antibody blockade and DT treatment For the PDL1 blockade experiments and the analysis of CD4 help dependence, CD4 T cells were depleted prior to LCMV infection by administering 125 mg of anti-CD4 antibody (GK1.5) to mice 3 days and then 1 day prior to infection. CD4 depletion was confirmed with flow cytometry using a non-blocking CD4 clone (RM4.4). For in vivo blocking experiments 250 mg of anti-PDL1 (10F.9G2) or isotype control (LTF-2) was administered i.p. starting 21 days post-cell transfer and then every 3 days for a total of 5 treatments. For IL-2 and IL-21R blockade experiments at the onset of Cl13 infection mice were treated with 500 mg of anti-IL-2 (S4B6-1), 300 mg of anti-IL-21R (mouse IgG1; Amgen) or appropriate RatIgG or Mouse IgG isotype controls one day following P14 injection and 8 hours prior to Cl13 infection, and every 2 days following for another 3 treatments. For IL-2 and IL-21R blockade in the midst of Cl13 infection, mice were treated with the same doses described above 4 hours prior to P14 injection (day 25 post LCMV-infection), then again 1 day later, and every subsequent 2 days until sacrifice 8 days post-P14 transfer. For in vivo agonistic antibody treatments persistently infected mice were treated i.p. with 200 mg anti-CD3 (1452C11) and/or 100 mg anti-CD28 (PV11) or an appropriate isotype control 4 hr after P14 transfer. All antibodies were obtained from BioXcell, except anti-IL-21R which was obtained from Amgen. For diphtheria toxin (DT)-mediated depletion of CD11c + DCs we administered either DT at 4 ng/g or control PBS to CD11c-DTR mice 18 hours prior to late P14 priming (D20 of Cl13 infection) and then again at 30 hr post-P14 transfer (48 hr after the initial DT treatment).
QUANTIFICATION AND STATISTICAL ANALYSIS Mass Cytometry and Flow Cytometry Analysis
Heatmaps were plotted in R using the viridis color package and the gplots package. All statistical parameters are described in the figure legends. Student's t tests (two-tailed, unpaired, or where indicated paired) and One-way ANOVA, multiple comparisons or two-way ANOVA, multiple comparisons were performed using GraphPad Prism 6 software (GraphPad Software, Inc.). In all figures, error bars indicate standard deviation.
RNaseq Analysis
Illumina reads were aligned to the Mus musculus GRCm38 genome build 88 using HISAT2. Alignments were compressed and sorted using SAMtools. The alignments were quantified using HTSeq to obtain gene counts. Differential analysis was conducted using edgeR using modified code from the rnaseq.wiki protocol. Low count genes were excluded from analysis if at least 3 samples did not have at least 1 CPM reads for that gene. Gene counts were normalized using Trimmed Mean of M-values (TMM) normalization.
Figures were plotted in R and the gplots package.
We performed a Gene Set Enrichment Analysis on the Enrichment Map gene set ''Mouse_GOBP_AllPathways_no_GO_iea_ August_01_2017_symbol.gmt'' and ImmuneSigDB using genes pre-ranked by edgeR p value. Immunoglobulin genes were excluded from the GSEA analysis. ImmuneSigDB gene lists were converted from human genes to orthologoue mouse genes using Ensembl BioMart.
DATA AND SOFTWARE AVAILABILITY
The RNA seq data generated in this paper has been deposited in the Gene Expression Omnibus (GEO) under accession number GEO: GSE105044.
